Your choice for ageing
patients with NVAF
Real-world evidence reinforces LIXIANA® as your DOAC of choice for ageing patients with NVAF1,2
Data from a 1-year snapshot analysis of an ongoing observational study in 12,574 patients with NVAF (ETNA-AF* Europe),1 treated with once-daily LIXIANA® (edoxaban), reinforced the findings of the pivotal phase 3 study (ENGAGE-AF** European Cohort).2,3
ETNA-AF supports the efficacy and safety profile of LIXIANA® in routine clinical practice.
Lower incidence of major bleeding and major GI bleeding
than in the pivotal phase 3 study†1,2
Lower incidence of stroke/SEE
than in the pivotal phase 3 study††1,2
Simple and convenient dosing, once daily, with or without food4
For illustration only, trials are not directly comparable
In patients with NVAF and high CrCl, there is a trend towards decreasing efficacy with increasing CrCl for edoxaban vs. well-managed warfarin, therefore careful evaluation of thromboembolic and bleeding risk is necessary before initiation.
ETNA-AF is the largest DOAC observational study of NVAF patients to date5
Key inclusion criteria:
Adult patients treated with LIXIANA® for NVAF according to the SmPC.5
Primary outcome measures:
Bleeding events; drug-related AEs; CV and all-cause mortality.5
Primary objective:
To assess the real-world safety and efficacy of LIXIANA® in NVAF patients in real-life clinical practice for up to 4 years.5
13,980 NVAF patients from 825 centres in 10 European countries enrolled5
ETNA-AF observational study design and baseline patient characteristics5
- 13,638 NVAF patients received standard dose LIXIANA® (60 mg) or reduced dose LIXIANA® (30 mg)‡5
- The mean patient age was 73.6 years‡5
ETNA-AF – Europe 1-year analysis: baseline patient characteristics2
Results from a 1-year snapshot analysis of the baseline and first outcomes data of 12,574 patients (89.9% of enrolled patients) who completed the 1-year follow-up visit (mean follow-up: 348 days) presented at ESC.2
Baseline patient characteristics were comparable to those in the ENGAGE-AF clinical trial.2
ETNA-AF – Europe 1-year analysis: baseline patient characteristics according to dose2
LIXIANA® in routine clinical practice:
ETNA-AF – Europe 1-year analysis1,2
Patients with AF receiving LIXIANA® in routine clinical practice in ETNA-AF – Europe had a lower incidence of major bleeding than the European cohort of ENGAGE-AF.1,2
For illustration only, trials are not directly comparable.
Patients with AF receiving LIXIANA® in routine clinical practice in ETNA-AF – Europe had numerically lower rates of major GI bleeding than the European cohort of ENGAGE-AF.1,2
For illustration only, trials are not directly comparable.
Patients with AF receiving LIXIANA® in routine clinical practice in ETNA-AF – Europe had a numerically lower incidence of intracranial haemorrhage to the European cohort of ENGAGE-AF.1,2
For illustration only, trials are not directly comparable.
The incidence of stroke/SEE was lower in patients who received LIXIANA® in routine clinical practice in ETNA-AF – Europe than the European cohort of ENGAGE-AF.1,2
The highest incidence of stroke/SEE was observed in patients receiving a reduced dose of LIXIANA® 30 mg in ENGAGE-AF.1,2
For illustration only, trials are not directly comparable.
All-cause mortality was higher in patients receiving LIXIANA® 30 mg O.D. in ETNA-AF – Europe vs. the European cohort of ENGAGE-AF.1,2
This would be consistent with this patient group also having a higher mean age (79.5 years vs. 75.6 years, respectively).1,2
For illustration only, trials are not directly comparable.
The CV mortality rate was lower in patients who received LIXIANA® in routine clinical practice in ETNA-AF than the European cohort of ENGAGE-AF.1,2
For illustration only, trials are not directly comparable.